Among these studies, carried out with various technological platforms of nanocarriers, some are in phase 1 and are directed, for example, at colon cancer, breast cancer, and B-cell non-Hodgkin lymphoma; others are in phase 2, such as those for basal cell carcinoma and prostate and HER2-positive metastatic breast cancer; some have reached phase 3, such as those concerning small-cell lung cancer (SCLC). The gene discussed is ERBB2; the disease is breast carcinoma.